Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2021; 9(26): 7643-7652
Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7643
Combined targeted therapy and immunotherapy for cancer treatment
Cheng-Xiang Guo, Xing Huang, Jian Xu, Xiao-Zhen Zhang, Yi-Nan Shen, Ting-Bo Liang, Xue-Li Bai
Cheng-Xiang Guo, Xing Huang, Jian Xu, Xiao-Zhen Zhang, Yi-Nan Shen, Ting-Bo Liang, Xue-Li Bai, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Author contributions: Guo CX and Huang X contributed equally to this work; Guo CX and Huang X contributed to concept and design and manuscript drafting; Xu J, Zhang XZ and Shen YN collected and summarized the relevant research information; Liang TB and Bai XL contributed to the critical manuscript revision; All authors have read and approve the final manuscript.
Supported by The National Key Research and Development Program of China, No. 2019YFC1316000, the National High Technology Research and Development Program of China, No. 2015AA020405, the National Natural Science Foundation of China, No. 81672337; and China Postdoctoral Science Foundation, No. 2020M671761.
Conflict-of-interest statement: The authors declare no potential conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Li Bai, MD, PhD, Chief Doctor, Executive Vice President, Professor, Research Scientist, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. shirleybai@zju.edu.cn
Received: June 8, 2021
Peer-review started: June 8, 2021
First decision: June 30, 2021
Revised: July 9, 2021
Accepted: July 28, 2021
Article in press: July 28, 2021
Published online: September 16, 2021
Processing time: 93 Days and 23.8 Hours
Core Tip

Core Tip: There has been considerable interest in combining systemic and immune-related therapies for the anti-tumor treatment of cancer. Additional insights into the effects and mechanisms of targeted therapies on the induction of anti-tumor immunity will aid the development and design of effective strategies, with the synergistic potential for rapid tumor regression and a durable response. Targeting specific signaling pathways may help in overcoming the mechanisms of immunotherapy resistance. We briefly review the immunomodulatory effects of targeted therapies and immunotherapies and discuss the obstacles associated with them, which may be useful for the development of novel basic research or clinical trials.